- Home
- CISO vs SBFM Comparison
CISO vs SBFM Comparison
Compare CISO & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- SBFM
- Stock Information
- Founded
- CISO 2015
- SBFM 2006
- Country
- CISO United States
- SBFM United States
- Employees
- CISO N/A
- SBFM N/A
- Industry
- CISO Computer Software: Prepackaged Software
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- CISO Technology
- SBFM Health Care
- Exchange
- CISO Nasdaq
- SBFM Nasdaq
- Market Cap
- CISO 8.3M
- SBFM 3.7M
- IPO Year
- CISO N/A
- SBFM N/A
- Fundamental
- Price
- CISO $0.88
- SBFM $3.06
- Analyst Decision
- CISO
- SBFM
- Analyst Count
- CISO 0
- SBFM 0
- Target Price
- CISO N/A
- SBFM N/A
- AVG Volume (30 Days)
- CISO 99.5K
- SBFM 121.6K
- Earning Date
- CISO 11-11-2024
- SBFM 11-11-2024
- Dividend Yield
- CISO N/A
- SBFM N/A
- EPS Growth
- CISO N/A
- SBFM N/A
- EPS
- CISO N/A
- SBFM N/A
- Revenue
- CISO $55,807,138.00
- SBFM $30,481,982.00
- Revenue This Year
- CISO $78.76
- SBFM $86.70
- Revenue Next Year
- CISO N/A
- SBFM $126.76
- P/E Ratio
- CISO N/A
- SBFM N/A
- Revenue Growth
- CISO 29.55
- SBFM 109.82
- 52 Week Low
- CISO $0.26
- SBFM $2.42
- 52 Week High
- CISO $3.60
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- CISO 57.14
- SBFM 49.32
- Support Level
- CISO $0.77
- SBFM $2.85
- Resistance Level
- CISO $1.08
- SBFM $3.05
- Average True Range (ATR)
- CISO 0.12
- SBFM 0.15
- MACD
- CISO -0.01
- SBFM 0.02
- Stochastic Oscillator
- CISO 53.55
- SBFM 63.89
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.